VALIANATOS, Georgios, Barbora VALČÍKOVÁ, Kateřina GROWKOVÁ, Amandine VERLANDE, Jitka VAŇÁČKOVÁ, Lenka RADOVÁ, Monika ŠTĚTKOVÁ, Michaela VYHŇÁKOVÁ, Ondřej SLABÝ and Stjepan ULDRIJAN. A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein. Plos one. San Francisco: Public Library of Science, 2017, vol. 12, No 10, p. 1-18. ISSN 1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0185801.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein
Authors VALIANATOS, Georgios (300 Greece, belonging to the institution), Barbora VALČÍKOVÁ (203 Czech Republic, belonging to the institution), Kateřina GROWKOVÁ (203 Czech Republic, belonging to the institution), Amandine VERLANDE (250 France, belonging to the institution), Jitka VAŇÁČKOVÁ (203 Czech Republic, belonging to the institution), Lenka RADOVÁ (203 Czech Republic, belonging to the institution), Monika ŠTĚTKOVÁ (203 Czech Republic, belonging to the institution), Michaela VYHŇÁKOVÁ (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Stjepan ULDRIJAN (203 Czech Republic, guarantor, belonging to the institution).
Edition Plos one, San Francisco, Public Library of Science, 2017, 1932-6203.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10600 1.6 Biological sciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.766
RIV identification code RIV/00216224:14110/17:00095215
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1371/journal.pone.0185801
UT WoS 000412131900055
Keywords in English MdmX transcript; MdmX protein; human cancer
Tags EL OK, OA, podil
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 15/3/2018 17:19.
Abstract
MdmX overexpression contributes to the development of cancer by inhibiting tumor suppressor p53. A switch in the alternative splicing of MdmX transcript, leading to the inclusion of exon 6, has been identified as the primary mechanism responsible for increased MdmX protein levels in human cancers, including melanoma. However, there are no approved drugs, which could translate these new findings into clinical applications. We analyzed the anti-melanoma activity of enoxacin, a fluoroquinolone antibiotic inhibiting the growth of some human cancers in vitro and in vivo by promoting miRNA maturation. We found that enoxacin inhibited the growth and viability of human melanoma cell lines much stronger than a structurally related fluoroquinolone ofloxacin, which only weakly modulates miRNA processing. A microarray analysis identified a set of miRNAs significantly dysregulated in enoxacin-treated A375 melanoma cells. They had the potential to target multiple signaling pathways required for cancer cell growth, among them the RNA splicing. Recent studies showed that interfering with cellular splicing machinery can result in MdmX downregulation in cancer cells. We, therefore, hypothesized that enoxacin could, by modulating miRNAs targeting splicing machinery, activate p53 in melanoma cells overexpressing MdmX. We found that enoxacin and ciprofloxacin, a related fluoroquinolone capable of promoting microRNA processing, but not ofloxacin, strongly activated wild type p53-dependent transcription in A375 melanoma without causing significant DNA damage. On the molecular level, the drugs promoted MdmX exon 6 skipping, leading to a dose-dependent downregulation of MdmX. Not only in melanoma, but also in MCF7 breast carcinoma and A2780 ovarian carcinoma cells overexpressing MdmX. Together, our results suggest that some clinically approved fluoroquinolones could potentially be repurposed as activators of p53 tumor suppressor in cancers overexpressing MdmX oncoprotein and that p53 activation might contribute to the previously reported activity of enoxacin towards human cancer cells.
Links
EE2.3.30.0009, research and development projectName: Zaměstnáním čerstvých absolventů doktorského studia k vědecké excelenci
GA14-12166S, research and development projectName: Regulace dráhy nádorového supresoru p53 novými vazebnými partnery onkogenů Mdm2 a Mdm4
Investor: Czech Science Foundation
MUNI/A/0810/2016, interní kód MUName: Molekulární a buněčná biologie
Investor: Masaryk University, Category A
PrintDisplayed: 18/7/2024 14:18